Table 3 Data comparison between studies comparing IBD incidence from FIT screening programs.
n | Rodriguez-Lago et al. | Bedi et al. |
|---|---|---|
110 | 191 | |
Median age | 57 | 58 |
Smoking history (%) | 10 | 12 |
Ulcerative Colitis (%) | 71.8 | 30.4 |
Crohn’s Disease (%) | 21.8 | 57.1 |
IBDU (%) | 6.4 | 12.5 |
UC distribution | ||
Proctitis (%) | 32 | 25.8 |
Left-sided (%) | 33 | 37.9 |
Extensive/pancolitis (%) | 35 | 36.2 |
CD distribution | ||
Ileal (%) | 42 | 14.7 |
Colonic (%) | 37 | 45 |
Ileocolonic (%) | 21 | 40.3 |
Upper gastrointestinal tract (%) | 0 | 0 |
Perianal (%) | 0 | 0 |
TI intubation (%) | 38 | 71.2 |
Any treatment (%) | 73.6 | 64.9 |
Oral Mesalamine (%) | 57.2 | 48.7 |
Rectal Mesalamine (%) | 30.9 | 17.8 |
Steroids (%) | 14.5 | 18.3 |
Azathioprine (%) | 5.5 | 6.8 |
Methotrexate (%) | 0.9 | 2.6 |
Biologic (%) | 1.8 | 17.8 |
Surgery (%) | 1.8 | 2.1 |
Follow-up period, median (months) | 25 | 25 |
